Regulatory Shift Positions Collegium Pharmaceutical for Growth

A significant policy development from the U.S. Food and Drug Administration (FDA) is creating a favorable environment for companies developing non-opioid pain therapies. Collegium Pharmaceutical, with its specific focus on abuse-deterrent formulations, appears exceptionally well-placed to benefit from this changing regulatory landscape.

The catalyst for this shift emerged on September 10th, when the FDA released new draft guidance designed to accelerate the development pathway for non-opioid analgesics targeting chronic pain. This initiative represents a strategic move by the agency to encourage safer alternatives to opioid-based medications and curb widespread prescription drug abuse.

For Collegium Pharmaceutical, this announcement arrives at a highly opportune moment. The company’s core business strategy, centered on creating responsible pain management therapies with built-in abuse-deterrent properties, aligns precisely with the FDA’s... Read more...

US19459J1043 | REGULATORY | boerse | 68183248 |